ZA200606065B - Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies - Google Patents

Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies

Info

Publication number
ZA200606065B
ZA200606065B ZA200606065A ZA200606065A ZA200606065B ZA 200606065 B ZA200606065 B ZA 200606065B ZA 200606065 A ZA200606065 A ZA 200606065A ZA 200606065 A ZA200606065 A ZA 200606065A ZA 200606065 B ZA200606065 B ZA 200606065B
Authority
ZA
South Africa
Prior art keywords
hyperglycaemia
acidic
prevention
treatment
quinoline derivatives
Prior art date
Application number
ZA200606065A
Other languages
English (en)
Inventor
Moinet Gerard
Arbellot De Vacqueur Annick
Correc Jean-Claude
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200606065B publication Critical patent/ZA200606065B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
ZA200606065A 2003-12-24 2006-07-21 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies ZA200606065B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0315402A FR2864535B1 (fr) 2003-12-24 2003-12-24 Derives acides de quinoline et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
ZA200606065B true ZA200606065B (en) 2007-12-27

Family

ID=34639610

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606065A ZA200606065B (en) 2003-12-24 2006-07-21 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies

Country Status (17)

Country Link
US (1) US7470708B2 (de)
EP (1) EP1696924B1 (de)
JP (1) JP4861828B2 (de)
KR (1) KR20060123369A (de)
CN (1) CN1893949A (de)
AR (1) AR046980A1 (de)
AT (1) ATE390136T1 (de)
AU (1) AU2004308578B2 (de)
BR (1) BRPI0417140A (de)
CA (1) CA2551227C (de)
DE (1) DE602004012770T2 (de)
ES (1) ES2302058T3 (de)
FR (1) FR2864535B1 (de)
MX (1) MXPA06007082A (de)
RU (1) RU2006126781A (de)
WO (1) WO2005063244A1 (de)
ZA (1) ZA200606065B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
AU2009243006B2 (en) * 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
PL228037B1 (pl) * 2009-03-23 2018-02-28 Marciniak Agnieszka Maria Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki
US8450369B1 (en) * 2011-08-02 2013-05-28 CIP Kemicals, Corp. Hypoglycemic oral drug for treating non-insulin dependent and insulin dependent diabetes
US8877811B1 (en) 2011-08-02 2014-11-04 CIP Kemicals, Corp. Hypoglycemic oral drug for treating non-insulin dependent and insulin dependent diabetes
CN115124462B (zh) * 2022-07-22 2023-08-22 浙江工业大学 2,3-二甲基-6,8-二氟喹啉-4-醚类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
ZA903588B (en) * 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
JPH03161441A (ja) * 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
FR2791263B1 (fr) * 1999-03-26 2001-04-27 Halina Zofia Malina Preparations des medicaments bases sur une reponse immunitaire contre l'accumulation de proteines modifiees par l'acide xanthurenique
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
EP1696924B1 (de) 2008-03-26
DE602004012770T2 (de) 2009-04-09
DE602004012770D1 (de) 2008-05-08
EP1696924A1 (de) 2006-09-06
MXPA06007082A (es) 2006-08-23
US7470708B2 (en) 2008-12-30
FR2864535B1 (fr) 2006-12-22
KR20060123369A (ko) 2006-12-01
BRPI0417140A (pt) 2007-02-21
JP4861828B2 (ja) 2012-01-25
AU2004308578B2 (en) 2010-11-11
AR046980A1 (es) 2006-01-04
CN1893949A (zh) 2007-01-10
ATE390136T1 (de) 2008-04-15
US20070149566A1 (en) 2007-06-28
RU2006126781A (ru) 2008-01-27
CA2551227A1 (en) 2005-07-14
WO2005063244A1 (en) 2005-07-14
CA2551227C (en) 2013-03-12
FR2864535A1 (fr) 2005-07-01
AU2004308578A1 (en) 2005-07-14
JP2007516986A (ja) 2007-06-28
ES2302058T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
EP1644021A4 (de) Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
IL174577A0 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ZA200707472B (en) Diosmetin derivatives for the treatment and prevention of thrombotic pathologies
EP1711197A4 (de) Verfahren und zusammensetzungen für die prävention und behandlung entzündlicher erkrankungen oder zustände
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
GB2418025B (en) Device for the prevention or treatment of ulcers
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
ZA200606065B (en) Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
EP1812797A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von hyperproliferationskrankheiten
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1671648A4 (de) Prävention und behandlung von gvhd
SI1680405T1 (sl) Bengamidni derivati in njihova uporaba za zdravljenje rakavih bolezni
IL143903A0 (en) Use of phanquinone for the treatment or prevention of memory impairment
GT200200281A (es) Metodos y composiciones para el tratamiento de patologias respiratorias
IL190842A0 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
EP1581246A4 (de) Porphyrin-derivate, verfahren zu ihrer herstellung und ihre verwendung in radioimmunotherapie
SI1644021T1 (sl) Postopki in sestavki za zdravljenje gastrointestinalnih motenj